Topics

PubMed Journals Articles About "Eculizumab Intervention Stage Liver Disease" RSS

07:28 EST 20th November 2019 | BioPortfolio

Eculizumab Intervention Stage Liver Disease PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest Eculizumab Intervention Stage Liver Disease articles that have been published worldwide.

More Information about "Eculizumab Intervention Stage Liver Disease" on BioPortfolio

We have published hundreds of Eculizumab Intervention Stage Liver Disease news stories on BioPortfolio along with dozens of Eculizumab Intervention Stage Liver Disease Clinical Trials and PubMed Articles about Eculizumab Intervention Stage Liver Disease for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Eculizumab Intervention Stage Liver Disease Companies in our database. You can also find out about relevant Eculizumab Intervention Stage Liver Disease Drugs and Medications on this site too.

Showing "Eculizumab intervention Stage Liver Disease" PubMed Articles 1–25 of 32,000+

Copeptin - a biomarker of short-term mortality risk (7 days) in patients with end-stage liver disease.

Background For many patients with end-stage liver disease, liver transplantation represents the only curative therapy. Transplant recipients are scored and ranked using the model for end-stage liver disease (MELD/MELD-Na). Circulatory impairment is known to deteriorate outcomes; however, it is not incorporated into the current allocation system's score. The aim of our study is to analyze the predictive value of copeptin as a biomarker of circulatory impairment and increased short-term mortality risk in pati...


Is living donor liver transplantation justified in high model for end-stage liver disease candidates (35+)?

Application of living donor liver transplantation (LDLT) in model for end-stage liver disease (MELD) 35+ patients has been regarded with skepticism. There is concern that a partial graft may not achieve favourable outcomes, and that a healthy donor is risked for a transplant which might turn out to be futile.

Trends in Hospitalizations for Chronic Liver Disease-related Liver Failure in the United States, 2005-2014.

Current estimates of the population-based disease burden of liver failure or end-stage liver disease (ESLD) are lacking. We investigated recent trends in hospitalizations and in-hospital mortality among patients with ESLD in the United States (US).


Intelligent Liver Function Testing (iLFT): A trial of automated diagnosis and staging of liver disease in Primary Care.

Liver function tests (LFTs) are frequently requested blood tests which may indicate liver disease. LFTs are commonly abnormal, the causes of which can be complex and frequently under investigated. This can lead to missed opportunities to diagnose and treat liver disease at an early stage. We developed an automated investigation algorithm, which would maximise early diagnosis of liver related diseases. Our aim was to determine whether this new pathway of care, Intelligent Liver Function testing (iLFT) increa...

Anesthesiological aspects of liver transplantation.

Liver transplantation (LTPL) is the only curative option for patients with end stage liver disease (ESLD) or with hepatocellular carcinoma (HCC). Eurotransplant in Leiden, the Netherlands, is responsible for organ allocation. The model of end stage liver disease (MELD) score, which describes the severity of the liver disease, is decisive for organ allocation. The heterogeneous patient collective and hepatic-related comorbidities and their dynamics represent challenges. The anesthesiologist is responsible fo...

Surgery in Patients with Portal Hypertension.

Patients with portal hypertension will increasingly present for nontransplant surgery because of the increasing incidence of, and improving long-term survival for, chronic liver disease. Such patients have increased perioperative morbidity and mortality caused by the systemic pathophysiology of liver disease. Preoperative assessment should identify modifiable causes of liver injury and distinguish between compensated and decompensated cirrhosis. Risk stratification, which is crucial to preparing patients an...

SARCOPENIA AND SEVERITY OF NON-ALCOHOLIC FATTY LIVER DISEASE.

Non-alcoholic fatty liver disease is characterized by deposition of lipids in the hepatic parenchyma exceeding 5% of liver weight in the absence of other conditions, such as viral or alcoholic hepatitis and metabolic disease. Non-alcoholic fatty liver disease is the most common form of chronic liver disease in several countries. In addition to liver complications, recent studies have shown a relation between liver fat and sarcopenia.

Impact of the Pediatric End-Stage Liver Disease (PELD) growth failure thresholds on mortality among pediatric liver transplant candidates.

The Pediatric End-stage Liver Disease (PELD) score is intended to determine priority for children awaiting liver transplant. This study examines the impact of PELD's incorporation of "growth failure" as a threshold variable, defined as having weight or height

Editorial: The 20% Rule of NASH Progression: The Natural History of Advanced Fibrosis and Cirrhosis due to NASH.

The global epidemic of obesity has led to the rise of non-alcoholic fatty liver disease (NAFLD) as a significant cause of cirrhosis, end-stage liver disease and need for liver transplantation.(1) NAFLD is common, with a global estimate of 25% of adults (2), however only a small proportion will progress to cirrhosis and develop liver related morbidity. As with other chronic liver diseases, the severity of underlying liver fibrosis aids prediction of outcome, with patients with bridging fibrosis or cirrhosis ...

The Candida albicans exotoxin Candidalysin promotes alcohol-associated liver disease.

Alcohol-associated liver disease is a leading indication for liver transplantation and leading cause of mortality. Alterations of the gut microbiota contribute to pathogenesis of alcohol-associated liver disease. Patients with alcohol-associated liver disease have increased proportions of Candida spp. in the fecal mycobiome. However, little is known about the effect of intestinal Candida on alcohol-associated liver disease. Here we evaluated the contributions of Candida albicans and its exotoxin Candidalysi...

Sarcopenia in chronic liver disease: impact on outcomes.

Malnutrition is a common complication in patients with end-stage liver disease (ESLD) awaiting liver transplantation (LTx). Malnutrition and sarcopenia overlap in etiology and outcomes, with sarcopenia being defined as reduced skeletal muscle mass (SMM) and muscle function. The purpose of this review was to identify the prevalence of sarcopenia with and without obesity in adult and children with ESLD, to assess the methodological considerations in sarcopenia diagnosis and the association of sarcopenia with ...

Modeling the natural history of fatty liver using lifestyle-related risk factors: Effects of body mass index (BMI) on the life-course of fatty liver.

Incident fatty liver increases the risk of non-alcoholic fatty liver disease (NAFLD), which may lead to end-stage liver diseases, and increase the risk of cardiovascular disease and diabetes. For its prevention, modeling the natural history of fatty liver is useful to demonstrate which lifestyle-related risk factors (e.g. body mass index and cholesterol) play the greatest role in the life-course of fatty liver.

The Impact of Chronic Liver Disease on Postoperative Outcomes and Resource Utilization.

Multiple studies have shown high rates of postoperative morbidity and mortality in individuals with chronic liver disease (CLD). However, analyses from comparisons with individuals without CLD are not available. Such analyses might provide opportunities to improve outcomes. Data from The National Surgical Quality Improvement Program (NSQIP) from 2008 to 2011 were analyzed comparing CLD patients undergoing non-liver surgery propensity matched to those without CLD. Patients with CLD were stratified by Model o...

Fat soluble vitamins deficiency in pediatric chronic liver disease: The impact of liver transplantation.

Children affected with chronic liver disease are at risk for fat-soluble vitamins (FSV) deficiency, in this scenario the role of liver transplant has been only partially explored.

COMPASS: A Pilot Trial of an Early Palliative Care Intervention for Patients with End Stage Liver Disease.

Palliative care interventions have shown promise in improving quality of life and reducing healthcare utilization among patients with chronic organ failure.

Rotavirus reassortant induced murine model of liver fibrosis parallels human biliary atresia.

Biliary atresia (BA) is a devastating neonatal cholangiopathy that progresses to fibrosis and end-stage liver disease by two years of age. Portoenterostomy may re-establish biliary drainage but, despite drainage, virtually all afflicted patients develop fibrosis and progress to end stage liver disease requiring liver transplantation for survival. In the murine model of BA, Rhesus rotavirus (RRV) infection of newborn pups results in a cholangiopathy paralleling human BA and has been used to study mechanistic...

It takes a village: primary care of the pediatric liver transplant recipient.

Long-term survival is now the rule rather than the exception for infants and children who undergo liver transplantation for end-stage liver disease, metabolic liver conditions and a variety of other indications. Pediatricians and primary care providers play vital roles in the care and management of this patient population. The purpose of this review is to highlight key aspects important to the care of the pediatric liver transplant recipient.

Model for End-Stage Liver Disease Score Predicts Development of First Episode of Spontaneous Bacterial Peritonitis in Patients With Cirrhosis.

To examine whether baseline model for end-stage liver disease (MELD) score in patients with cirrhosis and ascites predicts the future development of first spontaneous bacterial peritonitis (SBP) episode.

Pathophysiology of Cystic Fibrosis Liver Disease: a channelopathy leading to alterations in innate immunity and in microbiota.

Cystic fibrosis (CF) is a monogenic disease caused by mutation of Cftr. Cystic fibrosis associated liver disease (CFLD) is a common non-pulmonary cause of mortality in CF and accounts for about 2.5-5% of overall CF mortality. The peak of the disease is in the pediatric population but a second wave of liver disease in CF adults has been reported in the last decade in association with an increase in the life expectancy of these patients. New drugs are available to correct the basic defect in CF but their effi...

Membrane-filtration based plasma exchanges for atypical hemolytic uremic syndrome: Audit of efficacy and safety.

While complement blockade with eculizumab is recommended as first-line therapy of atypical hemolytic uremic syndrome (aHUS), plasma exchanges (PEX) remain the chief option for anti-factor H (FH) antibody associated disease and when access to eculizumab is limited.

Late diagnosis of hepatitis C virus infection, 2014-2016: continuing missed intervention opportunities.

Chronic hepatitis C virus (HCV) infection is typically asymptomatic until severe liver disease occurs and even then can remain undiagnosed for some time; thus, screening and treatment of asymptomatic persons are needed to prevent poor outcomes. In a previous analysis of data from between 2006 and 2011, we found that 17% of newly diagnosed HCV infections in 4 large health systems were among persons with cirrhosis and/or end-stage liver disease, termed "late diagnosis." We sought to determine the proportion w...

THE ROLE OF THE GUT MICROBIOTA IN LIVER DISEASE.

The gut microbiome is the natural intestinal inhabitant that has been recognized recently as a major player in the maintenance of human health and the pathophysiology of many diseases. Those commensals produce metabolites that have various effects on host biologic functions. Therefore, alterations in the normal composition or diversity of microbiome have been implicated in various diseases, including liver cirrhosis and nonalcoholic fatty liver disease. Moreover, accumulating evidence suggests that progress...

Obesity and Liver Disease: The New Era of Liver Transplantation.

Non-alcoholic fatty liver disease (NAFLD) is a spectrum that ranges from simple steatosis to steatohepatitis, advanced fibrosis and cirrhosis. NAFLD is now the most common chronic liver disease in many developed countries. The latest Organ Procurement and Transplantation Network and Scientific Registry of Transplant Recipients (OPTN/SRTR) annual liver transplant report showed that hepatitis C (HCV) infection was no longer the most common indication for liver transplant; instead "other/unknown etiology" beca...

Increased Risk of Death in First Year After Liver Transplantation Among Patients with Nonalcoholic Steatohepatitis vs Liver Disease of Other Etiologies.

An increasing number of patients with non-alcoholic steatohepatitis (NASH) require liver transplantation. We compared outcomes of patients with liver diseases of different etiologies (NASH, hepatitis C virus [HCV]-associated liver disease, and alcohol-associated liver disease [ALD]).

Complete response of early stage hepatocellular carcinoma in a patient treated with combination therapy of camrelizumab (SHR-1210) and apatinib.


Quick Search